As in human breast cancer [4], FMC presents an aggressive and infiltrative behavior [5,6], with both HER2-positive and triple negative (TN) subtypes showing worse prognosis than luminal A and B subtypes. This evidence concerns the gene ERBB2 and breast cancer.